Browse > Article
http://dx.doi.org/10.4062/biomolther.2009.17.3.299

Changes in the Pharmacokinetics of Rosiglitazone, a CYP2C8 Substrate, When Co-Administered with Amlodipine in Rats  

Kim, Seon-Hwa (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Kim, Kyu-Bong (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Um, So-Young (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Oh, Yun-Nim (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Chung, Myeon-Woo (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Oh, Hye-Young (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Choi, Ki-Hwan (Drug Metabolism Division, National Institute of Toxicological Research, Korea Food and Drug Administration)
Publication Information
Biomolecules & Therapeutics / v.17, no.3, 2009 , pp. 299-304 More about this Journal
Abstract
Rosiglitazone maleate (RGM) is widely used for improving insulin resistance. RGM is a moderate inhibitor of cytochrome P450 2C8 (CYP2C8) and is also mainly metabolized by CYP2C8. The aim of this study was to determine whether the effect of RGM on CYP2C8 is altered by co-treatment with other drugs, and whether amlodipine camsylate (AC) changes the pharmacokinetics (PK) of RGM. Of the 11 drugs that are likely to be co-administered with RGM in diabetic patients, seven drugs lowered the $IC_{50}$ value of RGM on CYP2C8 by more than 80%. In vitro CYP2C8 inhibitory assays of RGM in combination with drugs of interest showed that the $IC_{50}$ of RGM was decreased by 98.9% by AC. In a pharmacokinetic study, Sprague-Dawley (SD) rats were orally administered 1 mg/kg of RGM following by single or 10-consecutive daily administrations of 1.5 mg/kg/day of AC. No significant changes in the pharmacokinetic parameters of RGM were observed after a single administration of AC, but the AUC and $C_{max}$ values of RGM were significantly reduced by 36% and 31%, respectively, by multiple administrations of AC. In conclusion, RGM was found to be affected by AC by in vitro CYP2C8 inhibition testing, and multiple dosing of AC appreciably changed the pharmacokinetics of RGM. These findings suggest that a drug interaction exists between AC and RGM.
Keywords
Rosiglitazone maleate (RGM); Amlodipine camsylate (AC); Cytochrome P450 2C8 (CYP2C8); Pharmacokinetics (PK); Drug interaction;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Baldwin, S. J., Clarke, S. E. and Chenery, R. J. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. 48, 424-432   DOI   ScienceOn
2 Beconi, M., Mao, A., Creighton, M., Hop, C. E., Chiu, S. H., Eydelloth, R., Franklin, R., Tang, F., Yu, N. and Vincent, S. (2003). Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione in sulin sensitizer. Xenobiotica 33, 767-787   DOI   ScienceOn
3 Bun, S. S., Ciccolini, J., Bun, H., Aubert, C. and Catalin, J. (2003). Drug interactions of paclitaxel metabolism in human liver microsomes. J. Chemother. 15, 266-274   DOI   ScienceOn
4 Busby, W. F., Ackermann, J. M. and Crespi, C. L. (1999). Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos. 27, 246-249
5 Katoh, M., Nakajima, M., Shimada, N., Yamazaki, H. and Yokoi, T. (2000a). Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur. J. Clin. Pharmacol. 55, 843-852   DOI
6 Katoh, M., Nakajima, M., Yamazaki, H. and Yokoi, T. (2000b). Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm. Res. 17, 1189-1197   DOI   ScienceOn
7 Kim, K. B., Bartlett, M. G., Anand, S. S., Bruckner, J. V. and Kim, H. J. (2006). Rapid determination of the synthetic pyrethroid insecticide, deltamethrin, in rat plasma and tissues by HPLC. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 834, 141-148   DOI   ScienceOn
8 Mamidi, R. N., Benjamin, B., Ramesh, M. and Srinivas, N. R. (2003). Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomed. Chromatogr. 17, 417-420   DOI   ScienceOn
9 Muck, W. (1998). Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 56 (Suppl 1), 15-23 discussion 33   DOI
10 Ong, C. E., Coulter, S., Birkett, D. J., Bhasker, C. R. and Miners, J. O. (2000). The xenobiotic inhibitor profile of cytochrome P4502C8. Br. J. Clin. Pharmacol. 50, 573-580   DOI   ScienceOn
11 Guengerich, F. P., Brian, W. R., Iwasaki, M., Sari, M. A., Baarnhielm, C. and Berntsson, P. (1991). Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J. Med. Chem. 34, 1838-1844   DOI
12 Park, J. Y., Kim, K. A., Kang, M. H., Kim, S. L. and Shin, J. G. (2004). Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther. 75, 157-162   DOI   ScienceOn
13 Tracy, T. S., Korzekwa, K. R., Gonzalez, F. J. and Wainer, I. W. (1999). Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol. 47, 545-552   DOI   ScienceOn
14 Walsky, R. L., Gaman, E. A. and Obach, R. S. (2005). Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol. 45, 68-78   DOI
15 Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. and Collins, J. M. (1994). Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035
16 Niemi, M., Backman, J. T., Neuvonen, M. and Neuvonen, P. J. (2003a). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 46, 347-351   DOI
17 Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M. and Neuvonen, P. J. (2003b). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 46, 1319-1323   DOI
18 Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. and Harris, J. W. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546
19 Beresford, A. P., McGibney, D., Humphrey, M. J., Macrae, P. V. and Stopher, D. A. (1988). Metabolism and kinetics of amlodipine in man. Xenobiotica 18, 245-254
20 Muzeeb, S., Venkatesh, P., Mullangi, R. and Srinivas, N. R. (2006). Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica 36, 838-856   DOI   ScienceOn
21 Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. and Relling, M. V. (1995). Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275, 566-575
22 Hruska, M. W., Amico, J. A., Langaee, T. Y., Ferrell, R. E., Fitzgerald, S. M. and Frye, R. F. (2005). The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br. J. Clin. Pharmacol. 59, 70-79   DOI   ScienceOn
23 Muck, W. (2000). Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39, 99-116   DOI   ScienceOn
24 Connor, S. C., Hughes, M. G., Moore, G., Lister, C. A. and Smith, S. A. (1997). Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine. J. Pharm. Pharmacol. 49, 336-344   DOI   ScienceOn